ClinicalTrials.gg
Not yet recruitingNCT06911840APHRUpdated Jan 26, 2026

Male Factor Infertility Across India Using Aphrodite Criteria

An observational study in Male Infertility Due to Azoospermia, sponsored by Indira IVF Hospital Pvt Ltd. Not yet recruiting at 1 site in India. Open to male participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Primary conditionAzoospermiaRegistry: Infertility, MaleReclassifiedWhy we changed it
Registry
Infertility, Male — the first condition term the registry derived for this study.
ClinicalTrials.gg
Azoospermia
Why
  1. The study's listed conditions name Azoospermia, a narrower term within Infertility, Male.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Indira IVF Hospital Pvt Ltd · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,090
Sex
Male
01

Study summary

Study Purpose:

The purpose of this study is to conduct an observational cross-sectional analysis of male factor infertility across diverse regions of India utilizing the Aphrodite Criteria. This novel patient classification system offers a systematic approach to describing and managing male infertility, particularly for hypogonadal males with idiopathic infertility. The study aims to evaluate the current state of male fertility across India and identify any regional variations in male reproductive health and hypogonadism, which may be influenced by environmental, lifestyle, and genetic factors.

Study Objective:

The primary objective of this study is to conduct an observational cross-sectional analysis of male factor infertility across various regions of India using the Aphrodite Criteria. To reveal the prevalence and determinants of male factor infertility across different regions of India.

Hypothesis:

We hypothesize that there are significant regional differences in male factor infertility characteristics across India, with variations in sperm quality and testicular function due to diverse environmental, lifestyle, and genetic factors. Additionally, we hypothesize that the application of the Aphrodite Criteria will provide a more detailed classification of male infertility compared to conventional semen analysis and that certain lifestyle factors such as smoking, obesity, and occupational exposures will be associated with poorer sperm quality and testicular function.

Study Population:

The study population will consist of male patients visiting clinics across different IVF centers in India. The total sample size includes subjects from five groups with the following distribution:

35 subjects in Group I ; 416 subjects in Group II; 270 subjects in Group III; 152 subjects in Group IV; 216 subjects in Group V

The total sample size for all groups will be 1,090 subjects.

02

Conditions studied

  • Male Infertility Due to Azoospermia

Browse trials for

Keywords

  • Male infertility
  • Azoospermia
  • Aphrodite criteria
  • Prevelance
03

In context

Azoospermia Reclassified

59 studies on the registry are indexed under Azoospermia; 17 are open to participants now.

This study's planned enrollment of 1,090 is above the median of 95 across 24 observational studies indexed under Azoospermia.

Browse Azoospermia studies →

Lead sponsor

Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Compared within Azoospermia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility, Male. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All male visiting IVF clinics across different centres

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All male visiting IVF clinic willingly giving consent for andrological evaluation.

Exclusion criteria

Exclusion Criteria:

  • NONE
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,090 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    All the male population visiting IVF centre

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    No intervention

06

What researchers measure

Primary outcomes

  1. Prevalence of male infertility across the country

    Overall prevalence of male infertility according to the Aphrodite criteria in India.

    Time frame: 6 months

Secondary outcomes

  1. Prevalence of male infertility across various geographical distribution

    Prevalence of male infertility according to the Aphrodite criteria in different regions of India.

    Time frame: 6 months

  2. Factors associated with male infertility

    Factors associated with male infertility according to the Aphrodite criteria, both overall and stratified by region

    Time frame: 6 months

07

Study locations

1 site
  • Indira IVF Hospital
    Udaipur, Rajasthan 313001, India
    • Vipin Chandra, DGO · Contactdrvipinchandra@indiraivf.in · +91 9567971239
    • Sandro Esteves, MD,PhD · Sub investigator
    • Taruna Jhambh, MD · Sub investigator
    • Dayanidhi Kumar, MD · Sub investigator
    • Shyam Gupta, MD · Sub investigator
    • Nishtha Handa, MS · Sub investigator
    • Nisha Tiwari, DNB · Sub investigator
    • Tanu Batra, MD · Sub investigator
    • Pawan Yadav, MD · Sub investigator
    • Akanksha Jangid, MD · Sub investigator
    • Amol Lunkad, MD · Sub investigator
    • Amol Naik, DNB · Sub investigator
    • Rinoy Sreedharan, MD · Sub investigator
08

References and documents

Publications

  • Esteves SC, Yarali H, Vuong LN, Carvalho JF, Ozbek IY, Polat M, Le HL, Pham TD, Ho TM. Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients. Front Endocrinol (Lausanne). 2021 Mar 12;12:630550. doi: 10.3389/fendo.2021.630550. eCollection 2021. PubMed 33790862 ↗
  • May WL, Johnson WD. A SAS macro for constructing simultaneous confidence intervals for multinomial proportions. Comput Methods Programs Biomed. 1997 Jul;53(3):153-62. doi: 10.1016/s0169-2607(97)01809-9. PubMed 9230450 ↗
  • Esteves SC, Humaidan P, Ubaldi FM, Alviggi C, Antonio L, Barratt CLR, Behre HM, Jorgensen N, Pacey AA, Simoni M, Santi D. APHRODITE criteria: addressing male patients with hypogonadism and/or infertility owing to altered idiopathic testicular function. Reprod Biomed Online. 2024 Apr;48(4):103647. doi: 10.1016/j.rbmo.2023.103647. Epub 2023 Oct 29. PubMed 38367592 ↗

Individual participant data

Plan to share: Yes — The following supporting information will be made available as part of the data sharing plan: Study Protocol Available upon request or publication of study results. Statistical Analysis Plan (SAP) Will be shared with interested parties upon completion of the study. Informed Consent Form (ICF) A copy of the ICF will be available upon request from participating sites. Clinical Study Report (CSR) The final CSR will be shared once the study results are finalized and published. Analytic Code Will be shared alongside the study results for transparency and reproducibility of the findings.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After publication of the study and on request

Access criteria: Academic researchers, clinicians, and scientists involved in related fields of study. Regulatory Bodies: Organizations such as ethics committees, health authorities, and regulatory agencies that require access for monitoring and compliance purposes. Collaborators and Partners: Institutions or organizations collaborating on the study, subject to agreements for data sharing and confidentiality. What They Will Be Able to Access: Study Protocol: Complete details regarding the study design, objectives, and methodology. Statistical Analysis Plan (SAP): Full plan for data analysis, statistical methods, and handling of results. Informed Consent Form (ICF): Document outlining the consent process and participant rights, shared with participating researchers and ethics boards. Clinical Study Report (CSR): The final comprehensive report including all study findings, results, and conclusions. Analytic Code: The code used for statistical analysis, available for validation and reproducibility

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911840
Lead sponsor
Indira IVF Hospital Pvt Ltd
Responsible party
Dr Vipin Chandra (Chief Clinical Lab Operations, Indira IVF Hospital Pvt Ltd) — Principal investigator
First posted
Apr 4, 2025
Start date
Jan 23, 2026 (estimated)
Primary completion
Jun 23, 2026 (estimated)
Completion
Oct 23, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Vipin Chandra, DGO
Contact
ifa@indiraivf.in
+91- 9567971239

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion